About the Company
pieris pharmaceuticals is a clinical stage biotechnology company that discovers and develops anticalin-based drugs to target validated disease pathways in a unique and transformative way. our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled anticalin to treat uncontrolled asthma and a half-life-optimized anticalin to treat anemia. proprietary to pieris, anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. our libraries of more than 100 billion different anticalin proteins have repeatedly delivered drug candidates binding to a very broad spectrum of therapeutic targets. pieris has established a diverse pipeline of anticalin therapeutics for a number of different indications and has r&d collaborations with roche
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Employees
140
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $PIRS News
Pieris Pharmaceuticals Inc PIRS
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Why Are Pieris Pharmaceuticals Shares Tanking Today
Pieris Pharmaceuticals Inc (NASDAQ: PIRS) announced that partner AstraZeneca plc (NASDAQ: AZN) decided to discontinue and cease dosing in the ongoing clinical studies of elarekibep, an inhaled IL ...
Pieris Pharmaceuticals, Inc. (PIRS) stock forecast and price target
Find the latest Pieris Pharmaceuticals, Inc. PIRS analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.
Pieris Pharmaceuticals Inc PIRS
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Pieris Pharmaceuticals, Inc. (PIRS)
*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
Pieris Pharmaceuticals Inc
Picking the best bond ETF can be hard with so many options available. Here's what the experts suggest focusing on. Marijuana ETFs have had it rough lately, but risk-tolerant investors can tap ...
Pieris Pharmaceuticals, Inc. Common Stock (PIRS)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past ...
Pieris Pharmaceuticals, Inc.
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory ...
PIRS Pieris Pharmaceuticals, Inc.
The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.
Pieris Pharmaceuticals Inc.
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
Loading the latest forecasts...